-
1
-
-
78049401119
-
Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)
-
abstr 7506
-
Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28: abstr 7506.
-
(2010)
J. Clin. Oncol.
, vol.28
-
-
Belani, C.P.1
Waterhouse, D.M.2
Ghazal, H.3
-
2
-
-
77953541527
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
-
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
-
(2010)
Lancet Oncol.
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
-
3
-
-
75649135772
-
Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: Results from the phase III SATURN study
-
abstract A2.1
-
Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol 2009;4: S289 (abstract A2.1).
-
(2009)
J. Thorac. Oncol.
, vol.4
-
-
Cappuzzo, F.1
Coudert, B.P.2
Wierzbicki, R.3
-
4
-
-
59149092945
-
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
-
Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 591-598
-
-
Fidias, P.M.1
Dakhil, S.R.2
Lyss, A.P.3
-
5
-
-
77957042719
-
Maintenance with either gemcitabine of erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study
-
abstr 7507
-
Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine of erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010;28: abstr 7507.
-
(2010)
J. Clin. Oncol.
, vol.28
-
-
Perol, M.1
Chouaid, C.2
Milleron, B.J.3
-
6
-
-
34247882769
-
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature
-
Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-464.
-
(2007)
Oncologist
, vol.12
, pp. 451-464
-
-
Grossi, F.1
Aita, M.2
Follador, A.3
-
7
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
8
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
10
-
-
70350225538
-
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
-
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
-
(2009)
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
Brodowicz, T.2
Zielinski, C.3
-
11
-
-
77950975446
-
Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced nonsmall cell lung cancer? Implications for selection of patients for maintenance therapy
-
Sun JM, Park JO, Won YW, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced nonsmall cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 2010;5:540-545.
-
(2010)
J. Thorac. Oncol.
, vol.5
, pp. 540-545
-
-
Sun, J.M.1
Park, J.O.2
Won, Y.W.3
-
12
-
-
0037050354
-
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
-
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 85-91
-
-
Noda, K.1
Nishiwaki, Y.2
Kawahara, M.3
-
13
-
-
33646447066
-
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
-
Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 2038-2043
-
-
Hanna, N.1
Bunn Jr., P.A.2
Langer, C.3
-
14
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An openlabel randomised phase III trial
-
Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
15
-
-
77955092100
-
Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era
-
Ahn MJ, Lee J, Park YH, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010;5:1185-1196.
-
(2010)
J. Thorac. Oncol.
, vol.5
, pp. 1185-1196
-
-
Ahn, M.J.1
Lee, J.2
Park, Y.H.3
-
16
-
-
77954423520
-
Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: A collaborative epidemiologic study of the national hospital organization study group for lung cancer (NHSGLC) in Japan and a Southern California regional cancer registry databases
-
Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010;5:1001-1010.
-
(2010)
J. Thorac. Oncol.
, vol.5
, pp. 1001-1010
-
-
Kawaguchi, T.1
Matsumura, A.2
Fukai, S.3
-
17
-
-
85030590584
-
-
Dallas County, TX. Available at:, Accessed June 16, 2010
-
U. S. Census State and County Quick Facts: Dallas County, TX. Available at: http://quickfacts.census.gov/qfd/states/48/48113.html. Accessed June 16, 2010.
-
U. S. Census State and County Quick Facts
-
-
-
18
-
-
77958199124
-
Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
-
Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-1535.
-
(2010)
J. Thorac. Oncol.
, vol.5
, pp. 1529-1535
-
-
Rasco, D.W.1
Yan, J.2
Xie, Y.3
-
19
-
-
33749077728
-
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
-
Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 4405-4411
-
-
Weiss, G.J.1
Langer, C.2
Rosell, R.3
-
20
-
-
1642575171
-
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial
-
Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004;43:183-194.
-
(2004)
Lung Cancer
, vol.43
, pp. 183-194
-
-
Dancey, J.1
Shepherd, F.A.2
Gralla, R.J.3
Kim, Y.S.4
-
21
-
-
33847641797
-
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
-
Weiss GJ, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-460.
-
(2007)
Ann. Oncol.
, vol.18
, pp. 453-460
-
-
Weiss, G.J.1
Rosell, R.2
Fossella, F.3
-
22
-
-
77955097091
-
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer
-
Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010;5:1263-1272.
-
(2010)
J. Thorac. Oncol.
, vol.5
, pp. 1263-1272
-
-
Klein, R.1
Wielage, R.2
Muehlenbein, C.3
|